Sebastian Amigorena
Has grant
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Recent Grants
Grant: Close
Targeting eIF4A in melanoma persistent cells to prevent resistance
Open Date: 2018-07-01
Close Date: 2021-07-01
Grant: Close
Study and development of new anti-cancer therapeutic strategies based on immunomodulation and dendritic cells
Open Date: 2015-11-01
Close Date: 2019-10-31
Grant: Close
Phagosome functions and antigen cross presentation in primary dendritic cells
Open Date: 2014-09-01
Close Date: 2019-08-31
Grant: Close
Targeting of the Tn antigen by a specific chimeric monoclonal antibody in ovarian cancer immunotherapy
Open Date: 2011-04-01
Close Date: 2013-03-31
Grant: Close
Integrative phagosomal biology: antigen presentation and developmental programs in dendritic cells
Open Date: 2009-07-01
Close Date: 2014-06-30
Articles (9)
Thymomas are rare thymic epithelial tumors harboring a high but variable proportion of lymphocytes without obvious function. Autoimmunity is present in one third of patients at diagnosis. In this study, we performed a phenotypic, single-cell RNA sequencing and spatial analysis of both the T cells and tumoral cells. T cells at all stages of T-cell development—from immature to mature—were present in the tumor, suggesting active thymopoiesis in thymoma. However, data generated through multiple approaches suggested a maturation blockade at the double-negative to double-positive stage of T-cell development. In the mature T-cell compartment, the frequency of regulatory T cells was strongly decreased. The single-cell RNA sequencing analysis showed that the transcriptome of tumoral thymic epithelial cells (TEC) was most similar to that of nontumoral medullary TEC, but the expression of key molecules involved in positive and negative selection was defective. Multiplexed IHC consecutive staining revealed a loss of the cortex–medulla zoning in thymoma, which may be related to a decrease in the expression of T cell–targeted chemokines by tumoral TEC. Altogether, these results suggest that the thymopoiesis present in thymoma is abnormal and may be the cause of the prevalent autoimmunity observed in this disease.
Year:
2026
Recent advances in single-cell transcriptomics have illuminated intratumoral heterogeneity (ITH) in breast cancer, yet the spatial organization and functional states of immune populations within luminal tumors remain poorly understood. Here, we generated a spatially and clonally resolved single-cell immune atlas of early-stage luminal breast cancer by integrating paired single-cell RNA/TCR sequencing with multiplex immunohistochemistry across three spatially distinct tumor regions: central (core-proximal), intermediate and peripheral (invasive margin-proximal), in five patients. Peripheral regions are enriched in naïve CD4 T cells, monocytes, dendritic cells, and memory CD8 T cells with bystander properties, alongside TCF1 + exhausted progenitors (Tpex), and displayed elevated antigen presentation and tertiary lymphoid structures (TLS) signatures. In contrast, central regions harbor macrophages, clonally expanded regulatory T cells (Tregs), and two subsets of terminally exhausted CD8 T cells (Tex), one tissue-resident and one circulating, both expressing tumor-reactive features. Clonal overlap was observed between peripheral Tpex and central, tissue-resident Tex cells, revealing a spatially confined differentiation trajectory toward exhaustion within the tumor microenvironment. Central T cells also upregulate TGF-β signaling and metabolic pathways including fatty acid oxidation and oxidative phosphorylation, consistent with adaptation to an immunosuppressive microenvironment. Together, these findings reveal a spatially structured immune landscape in luminal breast cancer, marked by progressive immunosuppression from the tumor margin to the core, providing a framework for future region-specific immunotherapeutic strategies.
Year:
2025
Figure S8. DEGs of pMBRT vs Conv-PT comparison in all the clusters. , only genes up- or down-regulated with more than 0.411 log2 fold change (FC) (30% change) and adjusted p-value of less than 0.05 are considered as significantly DEGs. Genes with a log2FC > 1 or log2FC 200% change) are shown in a darker color and annotated in the graph.
Year:
2025
Treating radioresistant tumors like glioblastoma multiforme remains a challenge exacerbated by their immunosuppressive nature. Radiotherapy (RT) plays an immunomodulatory role, exerting both immunosuppressive and immunostimulatory effects. The nature of these effects depends on the total dose, dose per fraction, dose delivery method, and treatment length. Hypofractionation is observed to tip the balance toward immune stimulation. However, the use of hypofractionation is restricted in bulky tumors, such as gliomas, because of the high risk of toxicity. Therefore, finding new strategies leading to more favorable immune responses while reducing normal tissue toxicities could improve cancer treatment. In this study, we examine antitumoral immune responses to proton minibeam RT (pMBRT). Its immunomodulatory effects are not fully understood. To explore this, we conducted an in-depth characterization of the immune response to a curative dose of pMBRT in a preclinical orthotopic rat model of glioblastoma. Our findings revealed a close association between pMBRT and the immune response. pMBRT increased lymphocyte density in tumors more effectively than conventional proton therapy. Single-cell transcriptomics identified several immune cell types and unique transcriptional changes in tumor immune cells following pMBRT, including increased antibody production, chemotactic cytokine expression, and IFN responses. These results underscore the critical role of adaptive immunity, specifically T cells, in pMBRT's mechanism. The potential of pMBRT to trigger an antitumor immune response in a single RT session with minimal damage to healthy tissue makes it a promising candidate for future clinical trials and radioimmunotherapy combinations.
Year:
2025
Figure S10. Removal of contaminant in T cell subclustering. A) Reclustering of clusters C13-C17 of Fig. 5. B) Heatmap of top 10 most significantly differentially expressed genes per cluster. C) Expression of macrophage markers in the clusters confirms contamination, cluster 3 will be removed for following analysis
Year:
2025
Figure S9. Over-Representation Analysis (ORA), or pathway analysis, using Gene Ontology (GO) - Biological Process (BP) dataset of all the clusters that presented pathways. Pathways are curated to remove duplicates and ranked in descending order by pathway group and qvalue.
Year:
2025
Figure S1. Survival curves of RG2- glioma bearing rats: non-irradiated controls (black), rats receiving 30 Gy in Conv-PT (blue) and rats receiving 30 Gy average dose in pMBRT (red). The survival of the irradiated groups is significantly longer than the controls (p
Year:
2025
Human immune inflammatory response reflects the evolutionary adaptation of immune-cell regulatory elements 1 , where recent mutations can control both pathogen defence and susceptibility to chronic inflammatory and autoimmune diseases 2–4 . The impact of the deeper evolutionary history of these elements within primate genomes on human inflammatory responses remains poorly understood. Evolutionary young transposons have uniquely reshaped primate genomes 5 and spread novel cis -regulatory sequences 6 . To understand how these events influenced human inflammation, we traced sequence changes in annotated human immune-cell enhancers back to macaque. We show that Alu elements and endogenous retroviruses dispersed motifs for the inflammation-related NF-κB and IRF1, redefining their binding patterns and contributing most prominently to great ape-specific binding sites. After the human-macaque split, many of these motifs shifted toward higher predicted binding affinity. In humans, population genetics analyses reveal that positive selection favors alleles, often Alu-derived, that increase enhancer affinity toward NF-κB. Enhancers containing Alu elements are more likely to undergo positive selection at the locus level, particularly when associated with chronic inflammatory diseases. As the most mutable enhancer sequences, Alus harbor disproportionately high numbers of single nucleotide polymorphisms and significantly contribute to selected alleles, some associated with chronic inflammatory diseases. We propose that the invasion of primate-specific transposons has created unique opportunities to adapt inflammatory responses in rapidly evolving great apes, with ancestral Alus continuing to influence evolutionary potential in humans.
Year:
2025
In chronic infections and cancer, T cells are exposed to prolonged antigen stimulation, resulting in loss of function (or exhaustion) and impairment of effective immunological protection. Exhausted T cells are heterogeneous and include early progenitors (Tpex) and terminally exhausted cells (Tex). Here, we used bulk and single-cell transcriptomics to analyze expression of transposable elements (TEs) in subpopulations of mouse and human CD8 + tumor-infiltrating T lymphocytes (TILs). We show that in mice, members of the virus-like murine VL30 TE family (mostly intact, evolutionary young ERV1s) are strongly repressed in terminally exhausted CD8 + T cells in both tumor and viral models of exhaustion. Tpex expression of these VL30s, which are mainly intergenic and transcribed independently of their closest gene neighbors, was driven by Fli1, a transcription factor involved in progression from Tpex to Tex. Immune checkpoint blockade (ICB) in both mice and patients with cancer increased TE expression (including VL30 in mice), demonstrating that TEs may be applicable as ICB response biomarkers. We conclude that expression of TEs is tightly regulated in TILs during establishment of exhaustion and reprogramming by ICB. Analyses of TE expression on single cells and bulk populations open opportunities for understanding immune cell identity and heterogeneity, as well as for defining cellular gene expression signatures and disease biomarkers.
Year:
2023
Collaborators (10)
Renaud Leclere
Institut Curie
Emmanuel Clave
Université de Paris Faculté de Santé
Olivier Lantz
Institut Curie
Vahid Asnafi
-
Antoine Toubert
Head of laboratory
Université Paris Cité
Sylvain BAULANDE
Head
Institut Curie
Elina Zueva
Institut Curie
yolanda prezado
Centre National de la Recherche Scientifique (CNRS)
Ramon Ortiz
Assistant Professor
University Medical Center Groningen
Coralie Guerin
Co-Head of EVs platform
Institut Curie
Make your next move.
Prepare your application
Review drafts before you send them.